Bioversys published phase IIa early bactericidal activity data in the New England Journal of Medicine showing that alpibectir (BVL‑GSK098) combined with ethionamide demonstrated clinical proof‑of‑concept against pulmonary tuberculosis. The data support alpibectir’s mechanism as a resistance‑breaking agent that potentiates existing TB drugs, addressing an urgent need as drug resistance undermines current regimens. The NEJM publication provides peer‑reviewed validation of the combination’s activity and may accelerate development discussions with global health agencies and funders focused on multidrug‑resistant TB. The result bolsters antibiotics innovation at a time when new mechanisms are scarce.